Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.66 |
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.47 |
| ▸ | MAOA | P21397 | 4/20 | 0.46 |
| ▸ | MAOB | P27338 | 4/20 | 0.46 |
| ▸ | KRAS | P01116 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.45 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31078517 | 0.87 | HDAC6 (0.68) | HDAC6HDAC1PTGDR2CYP2C9HDAC10 | |
| SCHEMBL2247025 | 0.86 | PTGDR2 (0.60) | HDAC6HDAC1PTGDR2CYP2C9HDAC10 | |
| SCHEMBL2248432 | 0.85 | HDAC6 (0.66) | HDAC6HDAC1PTGDR2CYP2C9HDAC10 | |
| SCHEMBL2086484 | 0.85 | PTGDR2 (0.72) | HDAC6HDAC1PTGDR2CYP2C9PTGER2 | |
| SCHEMBL31078408 | 0.84 | HDAC6 (0.67) | HDAC6HDAC1PTGDR2CYP2C9HDAC10 | |
| SCHEMBL14067957 | 0.84 | HDAC1 (0.60) | HDAC6HDAC1PTGDR2CYP2C9HDAC10 | |
| SCHEMBL30506410 | 0.83 | HDAC6 (0.60) | HDAC6HDAC1PTGDR2HDAC10HDAC8 | |
| SCHEMBL21114856 | 0.83 | HDAC6 (0.60) | HDAC6HDAC1PTGDR2HDAC10HDAC8 | |
| SCHEMBL31078337 | 0.83 | HDAC6 (0.64) | HDAC6HDAC1PTGDR2CYP2C9HDAC10 | |
| SCHEMBL8097901 | 0.83 | HDAC6 (0.64) | HDAC6HDAC1PTGDR2CYP2C9HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008279-B2 | Compound—827 | ASTRAZENECA AB (SE) | 2011-08-30 | — | — | US | disclosed |
| US-8008279-B2 | Compound—827 | ASTRAZENECA AB (SE) | 2011-08-30 | — | — | US | disclosed |
| WO-2009001129-A9 | 1-CYANOCYCLOPROPYL-DERIVATIVES AS CATHEPSIN K INHIBITORS | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | WO | disclosed |
| US-20090012077-A1 | Novel Compound - 827 | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| US-20090012077-A1 | Novel Compound - 827 | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| WO-2009001129-A1 | 1-CYANOCYCLOPROPYL-DERIVATIVES AS CATHEPSIN K INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012077-A1 | Novel Compound - 827 | CTSS, CTSF, CTSB | HDAC6 121/4885HDAC1 340/4885PTGDR2 4076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.